75FCMC24F0164↗
Abt Global LLC received this contract from Ofc of Acquisition and Grants Management, Centers for Medicare and Medicaid Services: $6.39M obligated so far for health r&d services; health care - other; applied research. It runs to 2027-08-15, or to 2032-08-15 if every option is exercised.
Key facts · data as of Oct 25, 2026
- Recipient
- Abt Global LLC
- Awarding agency
- Centers for Medicare and Medicaid Services (Department of Health and Human Services)
- Contracting office
- Ofc of Acquisition and Grants Management (75FCMC)
- Obligated to date
- $6.39M
- Potential value
- $15.54M
- Ends
- 2027-08-15
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 25, 2026.
Cite this page: SpendQuery, Award 75FCMC24F0164, data as of Oct 25, 2026, https://spendquery.com/award?id=CONT_AWD_75FCMC24F0164_7530_75FCMC19D0080_7530
Abt Global LLC: all federal awards · Department of Health and Human Services: spending · Ofc of Acquisition and Grants Management: what it buys · The follow-on: recompete brief
NEW AWARD EVALUATION OF THE CELL AND GENE THERAPY ACCESS MODEL 75FCMC19D0080/75FCMC24F0135
Up for re-bid: ends 2027-08-15. Recompete brief →
What it is
- Product or service
- Health R&D Services; Health Care - Other; Applied Research (PSC AN42)
- Industry
- Research and Development in the Social Sciences and Humanities (NAICS 541720)
- Contracting office
- Ofc of Acquisition and Grants Management (75FCMC)
- Competition
- Full and open competition · 3 offers received
- Pricing
- Cost plus fixed fee
- How it was bought
- Multiple-award IDIQ · under 75FCMC19D0080
- Where the work is
- Baltimore, MD · district MD-07
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
5 actions since 2024-08-15. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-27 | P00004 | Administrative change | $0 | EVALUATION OF THE CELL AND GENE THERAPY ACCESS MODEL |
| 2026-05-18 | P00003 | Administrative change | $0 | EVALUATION OF THE CELL AND GENE THERAPY ACCESS MODEL. INCORPORATE FAR 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS (APRIL 2026) TO COMPLY WITH UPDATED FAR GUIDANCE IMPLEMENTING EXECUTIVE ORDER 14398. |
| 2025-05-27 | P00002 | Administrative change | -$1.50M | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI BILATERAL MODIFICATION TO DESCOPE PER EXECUTIVE ORDER 14222, IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE: CGT EVAL |
| 2024-12-06 | P00001 | Administrative change | $0 | NEW AWARD EVALUATION OF THE CELL AND GENE THERAPY ACCESS MODEL 75FCMC19D0080/75FCMC24F0135 |
| 2024-08-15 | 0 | $7.89M | NEW AWARD EVALUATION OF THE CELL AND GENE THERAPY ACCESS MODEL 75FCMC19D0080/75FCMC24F0135 |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-25). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗